Diagnosis and management of prolactin-secreting pituitary adenomas : a Pituitary Society international Consensus Statement
© 2023. Springer Nature Limited..
This Consensus Statement from an international, multidisciplinary workshop sponsored by the Pituitary Society offers evidence-based graded consensus recommendations and key summary points for clinical practice on the diagnosis and management of prolactinomas. Epidemiology and pathogenesis, clinical presentation of disordered pituitary hormone secretion, assessment of hyperprolactinaemia and biochemical evaluation, optimal use of imaging strategies and disease-related complications are addressed. In-depth discussions present the latest evidence on treatment of prolactinoma, including efficacy, adverse effects and options for withdrawal of dopamine agonist therapy, as well as indications for surgery, preoperative medical therapy and radiation therapy. Management of prolactinoma in special situations is discussed, including cystic lesions, mixed growth hormone-secreting and prolactin-secreting adenomas and giant and aggressive prolactinomas. Furthermore, considerations for pregnancy and fertility are outlined, as well as management of prolactinomas in children and adolescents, patients with an underlying psychiatric disorder, postmenopausal women, transgender individuals and patients with chronic kidney disease. The workshop concluded that, although treatment resistance is rare, there is a need for additional therapeutic options to address clinical challenges in treating these patients and a need to facilitate international registries to enable risk stratification and optimization of therapeutic strategies.
| Errataetall: |
ErratumIn: Nat Rev Endocrinol. 2023 Oct 17;:. - PMID 37848631 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Nature reviews. Endocrinology - 19(2023), 12 vom: 01. Dez., Seite 722-740 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 13.11.2023 Date Revised 22.03.2024 published: Print-Electronic ErratumIn: Nat Rev Endocrinol. 2023 Oct 17;:. - PMID 37848631 Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41574-023-00886-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361678169 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361678169 | ||
| 003 | DE-627 | ||
| 005 | 20240323000136.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41574-023-00886-5 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1341.xml |
| 035 | |a (DE-627)NLM361678169 | ||
| 035 | |a (NLM)37670148 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Petersenn, Stephan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Diagnosis and management of prolactin-secreting pituitary adenomas |b a Pituitary Society international Consensus Statement |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.11.2023 | ||
| 500 | |a Date Revised 22.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ErratumIn: Nat Rev Endocrinol. 2023 Oct 17;:. - PMID 37848631 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. Springer Nature Limited. | ||
| 520 | |a This Consensus Statement from an international, multidisciplinary workshop sponsored by the Pituitary Society offers evidence-based graded consensus recommendations and key summary points for clinical practice on the diagnosis and management of prolactinomas. Epidemiology and pathogenesis, clinical presentation of disordered pituitary hormone secretion, assessment of hyperprolactinaemia and biochemical evaluation, optimal use of imaging strategies and disease-related complications are addressed. In-depth discussions present the latest evidence on treatment of prolactinoma, including efficacy, adverse effects and options for withdrawal of dopamine agonist therapy, as well as indications for surgery, preoperative medical therapy and radiation therapy. Management of prolactinoma in special situations is discussed, including cystic lesions, mixed growth hormone-secreting and prolactin-secreting adenomas and giant and aggressive prolactinomas. Furthermore, considerations for pregnancy and fertility are outlined, as well as management of prolactinomas in children and adolescents, patients with an underlying psychiatric disorder, postmenopausal women, transgender individuals and patients with chronic kidney disease. The workshop concluded that, although treatment resistance is rare, there is a need for additional therapeutic options to address clinical challenges in treating these patients and a need to facilitate international registries to enable risk stratification and optimization of therapeutic strategies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Dopamine Agonists |2 NLM | |
| 650 | 7 | |a Prolactin |2 NLM | |
| 650 | 7 | |a 9002-62-4 |2 NLM | |
| 700 | 1 | |a Fleseriu, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Casanueva, Felipe F |e verfasserin |4 aut | |
| 700 | 1 | |a Giustina, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Biermasz, Nienke |e verfasserin |4 aut | |
| 700 | 1 | |a Biller, Beverly M K |e verfasserin |4 aut | |
| 700 | 1 | |a Bronstein, Marcello |e verfasserin |4 aut | |
| 700 | 1 | |a Chanson, Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Fukuoka, Hidenori |e verfasserin |4 aut | |
| 700 | 1 | |a Gadelha, Monica |e verfasserin |4 aut | |
| 700 | 1 | |a Greenman, Yona |e verfasserin |4 aut | |
| 700 | 1 | |a Gurnell, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Ho, Ken K Y |e verfasserin |4 aut | |
| 700 | 1 | |a Honegger, Jürgen |e verfasserin |4 aut | |
| 700 | 1 | |a Ioachimescu, Adriana G |e verfasserin |4 aut | |
| 700 | 1 | |a Kaiser, Ursula B |e verfasserin |4 aut | |
| 700 | 1 | |a Karavitaki, Niki |e verfasserin |4 aut | |
| 700 | 1 | |a Katznelson, Laurence |e verfasserin |4 aut | |
| 700 | 1 | |a Lodish, Maya |e verfasserin |4 aut | |
| 700 | 1 | |a Maiter, Dominique |e verfasserin |4 aut | |
| 700 | 1 | |a Marcus, Hani J |e verfasserin |4 aut | |
| 700 | 1 | |a McCormack, Ann |e verfasserin |4 aut | |
| 700 | 1 | |a Molitch, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Muir, Christopher A |e verfasserin |4 aut | |
| 700 | 1 | |a Neggers, Sebastian |e verfasserin |4 aut | |
| 700 | 1 | |a Pereira, Alberto M |e verfasserin |4 aut | |
| 700 | 1 | |a Pivonello, Rosario |e verfasserin |4 aut | |
| 700 | 1 | |a Post, Kalmon |e verfasserin |4 aut | |
| 700 | 1 | |a Raverot, Gerald |e verfasserin |4 aut | |
| 700 | 1 | |a Salvatori, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Samson, Susan L |e verfasserin |4 aut | |
| 700 | 1 | |a Shimon, Ilan |e verfasserin |4 aut | |
| 700 | 1 | |a Spencer-Segal, Joanna |e verfasserin |4 aut | |
| 700 | 1 | |a Vila, Greisa |e verfasserin |4 aut | |
| 700 | 1 | |a Wass, John |e verfasserin |4 aut | |
| 700 | 1 | |a Melmed, Shlomo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature reviews. Endocrinology |d 2009 |g 19(2023), 12 vom: 01. Dez., Seite 722-740 |w (DE-627)NLM187699860 |x 1759-5037 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2023 |g number:12 |g day:01 |g month:12 |g pages:722-740 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41574-023-00886-5 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2023 |e 12 |b 01 |c 12 |h 722-740 | ||